People · Operator
Named in public records as an officer, director or promoter · active 2017–2017 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Anelixis Therapeutics, Inc. | — | Biotechnology | Series A | $7.9M | $36.2M | 2017 |
Eric Craven at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Eric Craven on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Paul Sallaberry | 1 | 5 |
| Walter Ogier | 1 | 3 |
| James Heywood | 1 | 3 |
| Steven Perrin | 1 | 2 |
| WALTER C. OGIER | 1 | 2 |
| Theodore Reich | 1 | 1 |
| Maeve McNally | 1 | 1 |
| Augie Nieto | 1 | 1 |
| MAEVE C. MCNALLY | 1 | 1 |
| Kent Bransford | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.